U.S. markets closed

Edesa Biotech, Inc. (EDSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.14-0.14 (-2.65%)
At close: 4:00PM EDT
Sign in to post a message.
  • Y
    Ybirch
    Staying positive as the following weeks could be filled with positivity.

    03/09/21 - Completed their first cohort of EB01 2B enrollment - 29 Days later would be April 7 (add in time to compile results) information could be released prior to the shareholders meeting.
    03/15/21 - Achieved 50% enrollment in EB05 trial (It has 2 primary efficacy endpoints dates 28/60) 28 - April 12 60 - May 14. It is possible that they may share results after the 28 day efficacy endpoint. *Also could share this information prior to the shareholders meetings.
    04/22/21 - Shareholders meeting
    04/29/21 - Lifesci is hosting an KOL event with Dr. Theodore Steiner for Edesa on April 29 at 1pm. It was originally scheduled to host this event on April 8. Dr. Steiner is running a EB05 trial at Vancouver General.
  • S
    Steve-erino
    We need some good PR and institutional buy in to give us a boost. PLEASE!
  • A
    A star is born
    Nice post! This is $500M+ stock within a matter of days..they wouldn't hav e ]upped the agreement on Eb01 unless they knew it worked..two blockbuster drugs..lone government funded and trading like two bit stock

    "EB01 interim analysis with now global rights for multiple indications will provide interim results around April 7th to the 12th IMO..no later than the 18th.
    March 9th:
    "Once all the subjects in the first cohort complete the 28-day treatment, Edesa plans to initiate a blinded interim analysis. The interim results will determine the number of patients for the final part of the Phase 2b study based on probability thresholds previously approved by the Food and Drug Administration. "

    Interim results of EB05 is undetermined..it could be anytime if they are doing analysis of the first 50% dosed during phase II or after phase II..don't know..what we do know is they are already lining up phase III so things must be good...even though its a double blinded trial, they know if people are getting better when they usually don't..ARDS usually a death sentence.
    this stock is being played..buy all you can..going to $30 just on EB01.
    2 billion+ drugs late stage with efficacy findings soon"
  • a
    aj
    up 8% rn must be some news thats not public
    Bullish
  • J
    Joseph
    if u r a shareholder,u should have received annual report.anybody get one?? do we have shareholders here or just posters?
  • A
    AdT
    HGEN with 10 employees and less than $500K is annual revenues hit a market cap of $1.5+B today with medium positive news on their treatment. That's equivalent to EDSA at over $100/sh ... 18+ times the current price.
  • a
    aj
    beautiful comeback
    Bullish
  • a
    aj
    edsa to the moon📈📈📈📈in 2 to 4 business weeks
    Bullish
  • k
    kyle
    Theoretically could Vaxart turn Jansen’s covid vaccine into pill form?
  • A
    A star is born
    HGEN proves that EDESA will pop 50x current share price if results come in..and they should be reporting soon
  • J
    Juan Carlos
    What happens to this value?
    Neutral
  • S
    Steve
    Steve-1, More insider buys on Mar25, ceo 3000 & Pres 3500. Other news HGEN has finished phase 3 trial of their drug similar to EB05 & has a success rate of 54% in keeping people off ventilator
  • J
    Joseph
    if posters here are shareholders, you received the annual report this week. can anyone say what is on page 10 in regards to license agreements ? if you can't then I know your not a shareholder. aj if you bought 40000 shares,so u say,u should know this simple answer. keeping it real here.
  • a
    aj
    i think im gunna get out
  • D
    Dino
    When this gets approval 🚀🚀🚀
  • J
    Joseph
    aj. since buying at 7.35 did u buy more lower ?
  • S
    Steve
    Review of facts.
    1. July 30/2020, announced that they had tested EB05 on 120 healthy people for safety & tolerability. They injected the subjects with a potent inducer of acute systemic inflammation. They gave the subjects EB05 which resolved their fever, stabilized heart & breathing rates. Basically this is what Phase 1 testing consists of but Accesswire didn’t refer to it as such.
    2. Edesa has stated that phase 2 results will be available sometime in the month of April. Of note is that their annual shareholder meeting is scheduled for April 22.
    3. According to SEC filings Wainwright received a 7% discount on purchase price, so paid $5.95/sh. So with discounted price/sh & other stated fees, they stand to make $700,000.00 minimum.
    Hope this helps, and as always do your own DD.
  • A
    Afua
    i m sooo waiting.
  • S
    Steve
    Steve-1, HGEN up nearly 100% . We just need Edesa to be more effective then 54% . Hopefully this will push them to release Phase 2 results sooner.
  • a
    aj
    guys i was kidding i didnt get out EDSA TO THE MOON
    Bullish